Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 16/20 | 0.54 |
| ▸ | PDE7B | Q9NP56 | 4/20 | 0.54 |
| ▸ | PDE5A | O76074 | 4/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | PDE1A | P54750 | 2/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1819676 | 0.92 | PDE7A (0.54) | PDE7APDE7BPDE5APDE4DPDE1A | |
| SCHEMBL1813357 | 0.91 | PDE7A (0.53) | PDE7APDE7BPDE5APDE4DPDE1A | |
| SCHEMBL1815153 | 0.91 | PDE7A (0.61) | PDE7APDE7BPDE4D | |
| SCHEMBL1813908 | 0.90 | PDE7A (0.53) | PDE7APDE7BPDE5APDE4DPDE1A | |
| SCHEMBL1811087 | 0.90 | PDE7A (0.52) | PDE7APDE7BPDE5APDE4DPDE1A | |
| SCHEMBL1811767 | 0.90 | PDE7A (0.54) | PDE7APDE7BPDE5APDE4DPDE1A | |
| SCHEMBL1814230 | 0.88 | PDE7A (0.50) | PDE7APDE7BPDE5APDE4DPDE1A | |
| SCHEMBL5228275 | 0.85 | PDE7A (0.61) | PDE7APDE7BPDE5APDE4DPDE1A | |
| SCHEMBL1814067 | 0.82 | PDE7A (0.61) | PDE7APDE7BPDE4D | |
| SCHEMBL1813832 | 0.82 | PDE5A (0.48) | PDE5APDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943624-B2 | Pyridinylpyrazolopyrimidinone derivatives as PDE 7 inhibitors | ASUBIO PHARMA CO. LTD. (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943624-B2 | Pyridinylpyrazolopyrimidinone derivatives as PDE 7 inhibitors | ASUBIO PHARMA CO. LTD. (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943624-B2 | Pyridinylpyrazolopyrimidinone derivatives as PDE 7 inhibitors | ASUBIO PHARMA CO. LTD. (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-1636235-B1 | PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS | ASUBIO PHARMA CO LTD (JP) | 2009-10-14 | — | — | EP | disclosed |
| EP-1636235-B1 | PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS | ASUBIO PHARMA CO LTD (JP) | 2009-10-14 | — | — | EP | disclosed |
| US-20070270419-A1 | PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS | ASUBIO PHARMA CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270419-A1 | PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS | ASUBIO PHARMA CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270419-A1 | PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS | ASUBIO PHARMA CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20060128728-A1 | Pyridinylpyrazolopyrimidinone derivatives as pde 7 inhibitors | DAIICHI ASUBIO PHARMA CO., LTD (JP) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128728-A1 | Pyridinylpyrazolopyrimidinone derivatives as pde 7 inhibitors | PDE7A, PDE5A, PDE3A | PDE7A 1/4885PDE7B 6/4885PDE5A 2/4885 |
| US-20070270419-A1 | PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS | PDE7A, PDE5A, PDE3A | PDE7A 1/4885PDE7B 6/4885PDE5A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.